genXone Past Earnings Performance

Past criteria checks 0/6

genXone's earnings have been declining at an average annual rate of -40.9%, while the Biotechs industry saw earnings growing at 10.6% annually. Revenues have been declining at an average rate of 22.2% per year.

Key information

-40.9%

Earnings growth rate

-68.9%

EPS growth rate

Biotechs Industry Growth56.3%
Revenue growth rate-22.2%
Return on equity-35.7%
Net Margin-220.2%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Investors Holding Back On genXone S.A. (WSE:GX1)

Dec 06
Investors Holding Back On genXone S.A. (WSE:GX1)

Calculating The Fair Value Of genXone S.A. (WSE:GX1)

Sep 04
Calculating The Fair Value Of genXone S.A. (WSE:GX1)

genXone (WSE:GX1) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Feb 22
genXone (WSE:GX1) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Revenue & Expenses Breakdown

How genXone makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WSE:GX1 Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 242-430
30 Sep 242-330
30 Jun 242-430
31 Mar 242-430
31 Dec 232-430
30 Sep 233-440
30 Jun 233-340
31 Mar 234-240
31 Dec 2211040
30 Sep 2218540
30 Jun 2221640
31 Mar 2225940
31 Dec 2123930
30 Sep 2125940
30 Jun 2127930
31 Mar 21261030
31 Dec 2020720
30 Sep 2010310
30 Jun 206110
31 Mar 200-110
31 Dec 190-110
30 Sep 190-110
30 Jun 190-110
31 Mar 190-110
31 Dec 180-100
31 Dec 170000

Quality Earnings: GX1 is currently unprofitable.

Growing Profit Margin: GX1 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GX1 is unprofitable, and losses have increased over the past 5 years at a rate of 40.9% per year.

Accelerating Growth: Unable to compare GX1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GX1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.3%).


Return on Equity

High ROE: GX1 has a negative Return on Equity (-35.67%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/17 03:52
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

genXone S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.